Xeris Biopharma Holdings (XERS) Revenue Growth (3y) (2023 - 2026)
Xeris Biopharma Holdings (XERS) Revenue Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.01 Bn | 20.86 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 22.02 Bn | 22.02 Bn | - | - |
| 7 | Viatris | 20.40 Bn | 18.59 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.74 Bn | 12.31 Bn | 785.00 Mn | 2.94% |
| 10 | Xeris Biopharma Holdings | 1.42 Bn | 1.31 Bn | 72.55 Mn | 35.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.80% |
| Dec 31, 2025 | 37.31% |
| Sep 30, 2025 | 35.76% |
| Jun 30, 2025 | 41.40% |
| Mar 31, 2025 | 39.65% |
| Dec 31, 2024 | 41.02% |
| Sep 30, 2024 | 69.93% |
| Jun 30, 2024 | 75.41% |
| Mar 31, 2024 | 70.53% |
| Dec 31, 2023 | 84.61% |
| Sep 30, 2023 | 72.58% |